Clinical Trial

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Protocol Amendment History 5 changes
notable Trial sites expanded: 134 -> 159 locations 2026-08-01
notable Trial sites expanded: 118 -> 134 locations 2026-07-07
notable Trial sites expanded: 97 -> 118 locations 2026-06-03
notable Trial sites expanded: 44 -> 97 locations 2026-05-15
notable Trial sites expanded: 29 -> 44 locations 2026-04-02
Trial Details
NCT Number NCT07011719
Lead Sponsor Arcus Biosciences, Inc.
Conditions Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Enrollment 720 participants
Start Date 2025-09-08
Primary Completion 2028-04 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31